News

Lilly's cancer drug more effective than AbbVie's in head-to-head study
Eli Lilly said on Tuesday its drug, Jaypirca, was more effective in a head-to-head study against AbbVie's Imbruvica when ...
Eli Lilly’s Jaypirca succeeds in late-stage trial against Imbruvica of J&J and AbbVie
Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...
Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron
Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...
The 3 Things That Matter for Eli Lilly Now
Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...
Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)
Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s ...
EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales
Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...
Eli Lilly’s (LLY) Kisunla Gets FDA Approval for Safer Alzheimer’s Dosing Schedule
Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...